Evaluation of genotoxicity induced by exposure to antineoplastic drugs in lymphocytes of oncology nurses and pharmacists

Journal of Applied Toxicology

Volumn 33, Issue 3, 2013, Pages 196-201

  El Ebiary, Ahmad A ^a   Abuelfadl, Arwa A ^a   Sarhan, Naglaa I ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Antineoplastic drug; Chromosomal aberration; Genotoxicity; Lymphocyte; Micronucleus assay; Nurse; Pharmacist

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BIOLOGICAL MONITORING; CANCER CENTER; CELL COUNT; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTOXICITY; HUMAN; LYMPHOCYTE; MALE; MICRONUCLEUS; NURSE; PHARMACIST; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING;

ABNORMAL KARYOTYPE; ADULT; ANTINEOPLASTIC AGENTS; DNA DAMAGE; FEMALE; HEALTH FACILITY ENVIRONMENT; HUMANS; KARYOTYPING; LYMPHOCYTES; MALE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; MUTAGENS; NURSING STAFF, HOSPITAL; OCCUPATIONAL EXPOSURE; PHARMACISTS;

EID: 84873058446     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1735     Document Type: Article

References (31)

1. Baker ES, Connor TH. 1996. Monitoring occupational exposure to cancer chemotherapy drugs. Am. J. Health Syst. Pharm. 53: 2713-2723.
2. Berwick M, Vineis P. 2000. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J. Natl. Cancer Inst. 92: 874-897.
3. Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Cebulska-Wasilewska A, Fabianova E, Fucic A, Hagmar L, Joksic G, Martelli A, Migliore L, Mirkova E, Scarfi MR, Zijno A, Norppa H, Fenech M. 2007. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 28: 625-631.
4. Brumen V, Horvat D. 1996. Work environment influence on cytostatics induced genotoxicity in oncologic nurses. Am. J. Ind. Med. 30: 67-71.
5. Buckton KE, Evans HJ. 1973. Methods for the Analysis of Human Chromosome Aberrations. World Health Organization: Geneva.
6. Burgaz S, Karahalil B, Canli Z, Terzioglu F, Ancel G, Anzion RBM, Bos RP, Huttner E. 2002. Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Hum. Exp. Toxicol. 21: 129-135.
7. Cavallo D, Ursini CL, Perniconi B, Francesco AD, Giglio M, Rubino FM, Marinaccio A, Iavicoli S. 2005. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat. Res. 587: 45-51.
8. Cavallo D, Ursini CL, Omodeo-Sale E, Iavicoli S. 2007. Micronucleus induction and FISH analysis in buccal cells and lymphocytes of nurses administering antineoplastic drugs. Mutat. Res. 628: 11-18.
9. Deng H, Zhang M, He J, Wu W, Jin L, Zheng W, Lou J, Wang B. 2005. Investigating genetic damage in workers occupationally exposed to methotrexate using three genetic end-points. Mutagenesis 20: 351-357.
10. Ensslin AS, Huber R, Pethran A, Rommelt H, Schierl R, Kulka U, Fruhmann G. 1997. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics study. Int. Arch. Occup. Environ. Health 70: 205-208.
11. Fenech M, Morely AA. 1985. Measurement of micronuclei in lymphocytes. Mutat. Res. 147: 29-36.
12. Fuchs J, Hengstler JG, Jung D, Hiltl G, Konietzko J, Oesch F. 1995. DNA damage in nurses handling antineoplastic agents. Mutat. Res. 342: 17-23.
13. Fucic A, Jazbec A, Mijic A, Seso-Simic D, Tomek R. 1998. Cytogenetic consequences after occupational exposure to antineoplastic drugs. Mutat. Res. 416: 59-66.
14. Hagmar L, Bonassi S, Stromberg U, Brogger A, Knudsen LE, Norppa H, Reuterwall C. 1998. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res. 58: 4117-4121.
15. Hessel H, Radon K, Pethran A, Maisch B, Grombmair S, Sautter I, Fruhmann G. 2001. The genotoxic risk of hospital, pharmacy and medical personnel occupationally exposed to cytostatic drugs - evaluation by the micronucleus assay. Mutat. Res. 497: 101-109.
16. IARC. Available from: http://monographs.iarc.fr/index.php (accessed 29 May 2011).
17. Jakab MG, Major J, Tompa A. 2001. Follow-up genotoxicological monitoring of nurses handling antineoplastic drugs. J. Toxicol. Environ. Health 62: 307-318.
18. Kevekordes S, Gebel TW, Hellwig M, Dames W, Dunkelberg H. 1998. Human effect monitoring in cases of occupational exposure to antineoplastic drugs: a method comparison. Occup. Environ. Med. 55: 145-149.
19. Kopjar N, Garaj-Vrhovac V, Kasuba V, Rozgaj R, Ramic S, Pavlica V, Zeljezic D. 2009. Assessment of genotoxic risks in Croatian health care workers occupationally exposed to cytotoxic drugs: a multi-bio marker approach. Int. J. Hyg. Environ. Health 212: 414-431.
20. Laffon B, Teixeira JP, Silva S, Loureiro J, Torres J, Pásaro E, Méndez J, Mayan O. 2005. Genotoxic effects in a population of nurses handling antineoplastic drugs, and relationship with genetic polymorphisms in DNA repair enzymes. Am. J. Ind. Med. 48: 128-136.
21. Maluf SW, Erdtmann B. 2000. Follow up study of the genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. Mutat. Res. 471: 21-27.
22. Oestreicher U, Stephan G, Glatzel M. 1990. Chromosome and SCE analysis in peripheral lymphocytes of persons occupationally exposed to cytostatic drugs handled with and without use of safety covers. Mutat. Res. 242: 271-277.
23. Pilger A, Kohler I, Stettner H, Mader RM, Rizovski B, Terkola R, Diem E, Franz-Hainzl E, Konnaris C, Valic E, Rudiger HW. 2000. Long-term monitoring of sister chromatid exchanges and micronucleus frequencies in pharmacy personnel occupationally exposed to cytostatic drugs. Int. Arch. Occup. Environ. Health 73: 442-448.
24. Preston RJ, Dean BS, Galloway S, Holden H, McFee AF, Shelby M. 1987. Mammalian in vivo cytogenetic assays: analysis of chromosome aberrations in bone marrow cells. Mutat. Res. 189: 157-165.
25. Rekhadevi PV, Sailaja N, Chandrasekhar M, Mahboob M, Rahman MF, Grover P. 2007. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis 22: 395-401.
26. Rombaldi F, Cassini C, Salvador M, Saffi J, Erdtmann B. 2009. Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week. Mutagenesis 24: 143-148.
27. Surralles J, Natarajan AT. 1997. Human lymphocytes micronucleus assay in Europe. An international survey. Mutat. Res. 392: 165-174.
28. Turci R, Sottani C, Spagnoli G, Minoia C. 2003. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J. Chromatogr. 789: 169-209.
29. Valanis B, Vollmer WM, Labuhn KT, Glass AG. 1993. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs. 16: 288-295.
30. Watt JL, Stephen GS. 1986. Lymphocyte culture for chromosome analysis. In Human Cytogenetics: a Practical Approach, Rooney DE, Czepulkowski BH (eds). IRL Press: Oxford; 39-49.
31. Yoshida J, Kosaka H, Tomioka K, Kumagai S. 2006. Genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan. J. Occup. Health 48: 517-522.